DNA Stock Recent News

The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

- Company Revamps Pharmacogenomics Go-To-Market Strategy, Targets Validated PGx Assay Towards Specific Use Cases - STONY BROOK, NY / ACCESS Newswire / April 1, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), its wholly-owned clinical laboratory subsidiary, is repositioning its TR8™ PGx pharmacogenomics testing service to offer tailored subpanels for indication-specific use cases in addition to full panel testing. The first subpanel under ADCL's new go-to-market strategy is for the pre-emptive testing of patients with genetic variants of the DPYD gene that correlate to potentially reduced or absent DPD enzyme activity necessary to metabolize fluoropyrimidines, specifically capecitabine (branded Xeloda) and fluorouracil (5-FU), two chemotherapy drugs that are widely used as part of the standard of care treatment for patients with certain cancers.

The bankruptcy of consumer genetics testing company 23andMe last week led to widespread fears about the DNA of millions of Americans going on sale to the highest bidder. 23andMe has 15 million customers and with calls for users to delete their data, traffic to its website surged 526% on the day of its bankruptcy filing.

In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $6.59, denoting a -0.9% change from the preceding trading day.

Denver, Colorado--(Newsfile Corp. - March 27, 2025) -  247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that Kraig Biocraft Laboratories' (OTCQB: KBLB) ("Kraig Labs") groundbreaking achievement-successfully inserting the largest functional DNA construct ever recorded into silkworms-is set to redefine what's possible in synthetic biology and biotechnology. This technological leap doesn't merely advance the science; it dramatically expands Kraig's potential to deliver next-generation materials and products to multiple high-value markets.

23andMe has proposed a May 14 auction for the sale of its assets, which include the genetic data of more than 15 million customers. The sale of genetic data raises concerns about privacy and safety, and customers are worried about what this means for their personal information.

MILWAUKEE--(BUSINESS WIRE)--Fiserv, Inc. (NYSE: FI), a leading global provider of payments and financial services technology, today announced that Republic Bank & Trust Company (Republic Bank) has chosen the Fiserv award-winning DNA® platform to enhance the company's banking system capabilities and drive operational efficiencies to realize their digital transformation goals. With over $6 billion in assets and 47 banking centers, Republic Bank, a community bank headquartered in Louisville, K.

STONY BROOK, NY / ACCESS Newswire / March 26, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), the Company's wholly-owned clinical laboratory subsidiary, has submitted a validation package to the New York State Department of Health (NYSDOH) to request approval as a laboratory-developed test (LDT) for a PCR-based assay for the detection and subtyping of influenza A (H5) virus, also known as H5 bird flu, highly pathogenic avian influenza, or H5N1 (collectively "H5 bird flu"). ADCL's Linea™ Avian Influenza H5 Dx assay ("AIH5 Dx") is a highly sensitive, multi-target diagnostic assay capable of detecting and discriminating between pan-influenza A and H5 bird flu.

The genetic testing company 23andMe has filed for bankruptcy, prompting people who've used the service and sent in DNA samples to be analyzed to wonder what will happen to their genetic data.

DNA testing pioneer 23andMe filed for bankruptcy — sparking fresh concerns about safeguarding the personal data of the company's more than 15 million customers.